On Monday, Sarepta Therapeutics Inc (NASDAQ: SRPT) opened lower -3.10% from the last session, before settling in for the closing price of $121.61. Price fluctuations for SRPT have ranged from $75.85 to $173.25 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 32.89% over the past five years. Company’s average yearly earnings per share was noted 139.82% at the time writing. With a float of $89.66 million, this company’s outstanding shares have now reached $93.73 million.
Let’s look at the performance matrix of the company that is accounted for 1314 employees. In terms of profitability, gross margin is 85.39%, operating margin of 4.94%, and the pretax margin is 7.89%.
Sarepta Therapeutics Inc (SRPT) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Sarepta Therapeutics Inc is 6.13%, while institutional ownership is 92.43%. The most recent insider transaction that took place on Aug 30 ’24, was worth 822,100. In this transaction Chief Financial Officer of this company sold 5,985 shares at a rate of $137.36, taking the stock ownership to the 33,946 shares. Before that another transaction happened on Aug 30 ’24, when Company’s Officer proposed sale 5,985 for $137.37, making the entire transaction worth $822,130.
Sarepta Therapeutics Inc (SRPT) Latest Financial update
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted 0.47 earnings per share (EPS) for the quarter, besting the agreed prediction (set at 0.01) by 0.46. Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 139.82% per share during the next fiscal year.
Sarepta Therapeutics Inc (NASDAQ: SRPT) Trading Performance Indicators
Check out the current performance indicators for Sarepta Therapeutics Inc (SRPT). In the past quarter, the stock posted a quick ratio of 3.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.20, a number that is poised to hit 1.54 in the next quarter and is forecasted to reach 11.68 in one year’s time.
Technical Analysis of Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc (NASDAQ: SRPT) saw its 5-day average volume 1.46 million, a positive change from its year-to-date volume of 1.23 million. As of the previous 9 days, the stock’s Stochastic %D was 19.85%. Additionally, its Average True Range was 4.52.
During the past 100 days, Sarepta Therapeutics Inc’s (SRPT) raw stochastic average was set at 2.93%, which indicates a significant decrease from 8.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 34.15% in the past 14 days, which was lower than the 51.24% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $125.56, while its 200-day Moving Average is $130.62. Nevertheless, the first resistance level for the watch stands at $121.14 in the near term. At $124.43, the stock is likely to face the second major resistance level. The third major resistance level sits at $126.24. If the price goes on to break the first support level at $116.04, it is likely to go to the next support level at $114.23. The third support level lies at $110.94 if the price breaches the second support level.
Sarepta Therapeutics Inc (NASDAQ: SRPT) Key Stats
There are currently 95,520K shares outstanding in the company with a market cap of 11.37 billion. Presently, the company’s annual sales total 1,243 M according to its annual income of -535,980 K. Last quarter, the company’s sales amounted to 362,930 K and its income totaled 6,460 K.
